1. Phylogeny  
   Non‐receptor tyrosine‐protein kinase TYK2 is a member of the Janus kinase (JAK) family, which comprises four paralogs in humans: JAK1, JAK2, JAK3, and TYK2. TYK2 is evolutionarily conserved among vertebrates and is traced back to early eukaryotic ancestors that diversified into the modern metazoan kinase repertoire (lupardus2014structureofthe pages 1-2, li2017insightsontype pages 9-14). In phylogenetic analyses, TYK2 groups with the JAK family within the tyrosine kinase superfamily and shows closer homology to JAK1 than to JAK2 or JAK3. The conservation of domain structure—with N-terminal FERM and SH2 domains, a central pseudokinase domain, and a C-terminal catalytic (JH1) domain—reflects its ancient origins and indicates that the regulatory mechanisms observed in TYK2 were already established in the Last Eukaryotic Common Ancestor (lupardus2014structureofthe pages 1-2, li2017insightsontype pages 9-14).
2. Reaction Catalyzed  
   TYK2 catalyzes the phosphorylation reaction in which a phosphate group is transferred from ATP to specific tyrosine residues on its substrate proteins. In the context of cytokine signaling, its enzymatic activity is best summarized by the equation:  
     ATP + [protein]-Tyr → ADP + [protein]-pTyr + H⁺  
   This reaction is critical to the signal transduction cascade initiated by cytokine binding to receptor complexes, ultimately leading to the activation of STAT transcription factors (argiriadi2012enablingstructurebaseddrug pages 10-11).
3. Cofactor Requirements  
   The catalytic activity of TYK2 is dependent on the binding of ATP as a phosphate donor and requires the presence of divalent metal ions, particularly Mg²⁺, which act as essential cofactors by stabilizing the phosphate groups during the transfer reaction and assisting in proper substrate orientation within the active site (bayliss2015theysand pages 20-25, min2015structuralandfunctional pages 10-11).
4. Substrate Specificity  
   TYK2 displays substrate specificity primarily for tyrosine residues present in the intracellular domains of cytokine receptors and, upon receptor engagement, in members of the STAT protein family. Although a strict consensus phosphorylation motif has not been unequivocally defined, TYK2-mediated phosphorylation occurs within receptor chains such as IFNAR1, IL12RB1, IL10RB, and IL13RA1—as well as on STAT proteins (STAT1, STAT3, STAT4, and sometimes STAT6)—thereby generating phosphotyrosine docking sites essential for subsequent signal propagation (argiriadi2012enablingstructurebaseddrug pages 10-11, sohn2013arestrictedrole pages 12-13, borcherding2021tyk2incancer pages 5-6).
5. Structure  
   TYK2 is organized into a modular structure typical of the JAK family. Its N-terminal region comprises a FERM (four-point-one, ezrin, radixin, moesin) domain that mediates binding to specific motifs in cytokine receptor cytoplasmic tails; this is followed by an SH2-like domain that further contributes to receptor association. Centrally located, the pseudokinase domain (JH2) does not exhibit full catalytic activity but plays a critical regulatory role by maintaining autoinhibition and serving as a scaffolding module for proper receptor complex assembly. The C-terminal region contains the kinase or JH1 domain that performs the phosphorylation of tyrosine residues (lupardus2014structureofthe pages 1-2, min2015structuralandfunctional pages 1-2).  
   High-resolution crystallographic studies have revealed that the tyrosine kinase domain adopts a bilobal configuration typical of protein kinases, with the smaller N-terminal lobe and the larger C-terminal lobe forming a deep cleft that accommodates ATP; critical structural elements include an activation loop whose phosphorylation state modulates catalytic activity, a hydrophobic spine that stabilizes the active conformation, and an αC helix that is essential for proper orientation of catalytic residues (lupardus2014structureofthe pages 2-3, min2015structuralandfunctional pages 4-6).  
   Unique among kinases, the TYK2 pseudokinase domain maintains an ATP-binding pocket despite lacking several conserved catalytic residues; it binds ATP in a non‐canonical manner and exerts an autoinhibitory effect on the adjacent catalytic domain. Structural comparisons with other JAK members reveal that while the overall fold is conserved, subtle differences—such as the positioning of the αC helix and the conformation of the activation segment—confer ligand binding selectivity and contribute to differential regulatory behavior (min2015structuralandfunctional pages 7-8, li2017insightsontypea pages 30-33).
6. Regulation  
   Regulation of TYK2 activity is multifaceted and involves both intrinsic and extrinsic mechanisms. One key regulatory mechanism is autoinhibition mediated by the pseudokinase domain (JH2), which interacts with the kinase domain (JH1) to suppress its basal activity. Upon cytokine binding, conformational changes relieve this inhibition through trans‐phosphorylation events, particularly within the activation loop of the kinase domain, thereby enabling full catalytic activation (min2015structuralandfunctional pages 10-11, li2017insightsontypea pages 88-89).  
   Post-translational modifications play a central role in regulating TYK2. Phosphorylation of tyrosine residues within the activation loop is critical for catalytic competence, and these phosphorylation events can occur via autophosphorylation or through trans‐phosphorylation by partner JAKs in the receptor complex. In addition, regulatory proteins such as suppressors of cytokine signaling (SOCS), particularly SOCS1 and SOCS3, interact with TYK2 to inhibit its kinase activity and may promote its ubiquitination and degradation (sohn2013arestrictedrole pages 12-13, li2017insightsontypea pages 88-89).  
   Furthermore, binding of ATP to the pseudokinase domain, although not resulting in a typical catalytic reaction, enhances the structural stability of TYK2 and contributes to its precise regulation by maintaining a conformation that is poised for activation upon appropriate receptor engagement (min2015structuralandfunctional pages 6-7).
7. Function  
   TYK2 plays a central role in the signal transduction cascades initiated by various cytokines, notably type I interferons (IFN-α/β) and interleukins such as IL-12, IL-23, IL-10, and IL-13. In response to cytokine binding to their heterodimeric receptors, TYK2 phosphorylates specific tyrosine residues on the receptor subunits, enabling the recruitment and subsequent phosphorylation of STAT transcription factors. Activated STATs then dimerize and translocate to the nucleus, where they modulate the transcription of genes involved in the regulation of cell growth, development, migration, and both innate and adaptive immune responses (argiriadi2012enablingstructurebaseddrug pages 10-11, borcherding2021tyk2incancer pages 3-5).  
   TYK2’s role extends beyond its catalytic activity; it also functions structurally to stabilize receptor complexes such as the type I interferon receptor (IFNAR1) and components of the IL-12/23 receptor systems. This dual functionality underpins its position as a pivotal mediator within the immune signaling network, influencing the differentiation of T helper cell subsets (notably Th1 and Th17), the activation of innate immune cells, and the orchestration of antiviral responses (muromoto2022currentunderstandingof pages 10-11, borcherding2021tyk2incancer pages 18-20).  
   Expression of TYK2 is widespread among hematopoietic and nonhematopoietic cells, with particularly high levels in immune tissues where rapid and robust cytokine signaling is required. Its activity is indispensable for the proper development and function of various immune cell types, including natural killer (NK) cells, dendritic cells, and T lymphocytes (argiriadi2012enablingstructurebaseddrug pages 10-11, muromoto2022currentunderstandingof pages 2-4).
8. Other Comments  
   Selective pharmacological inhibition of TYK2 has emerged as a promising therapeutic strategy for the treatment of immune-mediated inflammatory diseases. Recent drug discovery efforts have focused on developing inhibitors that target the unique allosteric site within the pseudokinase domain, thereby providing high selectivity over other members of the JAK family. For example, compounds such as deucravacitinib are designed to bind to the regulatory region of TYK2 with reduced off-target activity, offering potential advantages over pan‐JAK inhibitors that exhibit broader immunosuppressive effects (rusinol2023tyk2targetingin pages 1-3, dymock2014selectivejakinhibitors. pages 24-25).  
   In addition, genetic variants of TYK2 have been linked to altered cytokine signaling and differential susceptibility to autoimmune disorders. Certain hypomorphic alleles, including the well‐characterized P1104A variant, result in diminished kinase activity while still retaining sufficient scaffolding function, leading to a protective effect against diseases such as multiple sclerosis and systemic lupus erythematosus (li2017insightsontypea pages 88-89, li2013tworarediseaseassociated pages 9-9). Conversely, overexpression or constitutive activation of TYK2, as observed in some malignancies, contributes to pathological signaling via persistent STAT activation, thereby enhancing cell proliferation and survival (borcherding2021tyk2incancer pages 14-16, turrubiartesmartinez2020tyk2variantsin pages 15-16).  
   Thus, TYK2 represents a critical nodal point in cytokine receptor signaling cascades with significant implications for the development of targeted therapies in both autoimmune and oncological indications. Ongoing efforts to elucidate detailed structure–function relationships promise to further refine the design of next-generation selective inhibitors with improved safety and efficacy profiles (krueger2022tyrosinekinase2 pages 1-2, woss2019tyk2anupstream pages 5-6).
9. References
10. Argiriadi, M. A., Goedken, E. R., Banach, D., Borhani, D. W., Burchat, A., Dixon, R. W., … & Talanian, R. V. (2012). Enabling structure-based drug design of TYK2 through co-crystallization with a stabilizing aminoindazole inhibitor. BMC Structural Biology, 12:22. (argiriadi2012enablingstructurebaseddrug pages 10-11)
11. Borcherding, D. C., He, K., Amin, N. V., & Hirbe, A. C. (2021). TYK2 in cancer metastases: genomic and proteomic discovery. Cancers, 13:4171. (borcherding2021tyk2incancer pages 3-5, pages 5-6, pages 14-16, pages 18-20, pages 6-8)
12. Gakovic, M. (2007). Functional studies of TYK2 in IFNα signaling: A new interactor and an activating mutation. [Peer-reviewed journal]. (gakovic2007functionalstudiesof pages 32-36, pages 22-25, pages 36-39, pages 99-103)
13. Gerstenberger, B. S., Ambler, C., Arnold, E. P., Banker, M.-E., Brown, M. F., Clark, J. D., … & Wright, S. W. (2020). Discovery of tyrosine kinase 2 (TYK2) inhibitor (PF-06826647) for the treatment of autoimmune diseases. Journal of Medicinal Chemistry, 63:13561-13577. (gerstenberger2020discoveryoftyrosine pages 1-2)
14. Li, Z. (2017). Insights on type I IFN signaling and regulation: studies of disease-associated TYK2 variants and of the negative regulators USP18/ISG15. [Peer-reviewed journal]. (li2017insightsontype pages 9-14, pages 14-20, pages 22-26)
15. Li, Z. (2017). Insights on type I IFN signaling and regulation: studies of disease-associated TYK2 variants and of the negative regulators USP18/ISG15. [Peer-reviewed journal]. (li2017insightsontypea pages 14-20, pages 22-26, pages 88-89, pages 30-33, pages 33-37)
16. Lupardus, P. J., Ultsch, M., Wallweber, H., Kohli, P. B., Johnson, A. R., & Eigenbrot, C. (2014). Structure of the pseudokinase–kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition. Proceedings of the National Academy of Sciences, 111:8025-8030. (lupardus2014structureofthe pages 1-2, pages 2-3, pages 5-6)
17. Min, X., Ungureanu, D., Maxwell, S., Hammarén, H., Thibault, S., Hillert, E.-K., … & Wang, Z. (2015). Structural and functional characterization of the JH2 pseudokinase domain of JAK family tyrosine kinase 2 (TYK2). Journal of Biological Chemistry, 290:27261-27270. (min2015structuralandfunctional pages 1-2, pages 4-6, pages 7-8, pages 10-11, pages 11-13, pages 13-14, pages 6-7, pages 7-8)
18. Muromoto, R., Oritani, K., & Matsuda, T. (2022). Current understanding of the role of tyrosine kinase 2 signaling in immune responses. World Journal of Biological Chemistry, 13:1-14. (muromoto2022currentunderstandingof pages 1-2, pages 2-4, pages 6-7, pages 8-10, pages 10-11)
19. Rusinol, L., & Puig, L. (2023). TYK2 targeting in immune-mediated inflammatory diseases. International Journal of Molecular Sciences, 24:3391. (rusinol2023tyk2targetingin pages 1-3)
20. Sohn, S. J., Barrett, K., Van Abbema, A., Chang, C., Kohli, P. B., Kanda, H., … & Wu, L. C. (2013). A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors. The Journal of Immunology, 191:2205-2216. (sohn2013arestrictedrole pages 12-13, pages 2-3, pages 4-5)
21. Tokarski, J. S., Zupa-Fernandez, A., Tredup, J. A., Pike, K., Chang, C.-Y., Xie, D., … & Burke, J. R. (2015). Tyrosine kinase 2-mediated signal transduction in T lymphocytes is blocked by pharmacological stabilization of its pseudokinase domain. Journal of Biological Chemistry, 290:11061-11074. (tokarski2015tyrosinekinase2mediated pages 1-2)
22. Turrubiartes-Martínez, E., Bodega-Mayor, I., Delgado-Wicke, P., Molina-Jiménez, F., Casique-Aguirre, D., González-Andrade, M., … & Fernández-Ruiz, E. (2020). TYK2 variants in B-acute lymphoblastic leukemia. Genes, 11:1434. (turrubiartesmartinez2020tyk2variantsin pages 15-16)
23. Wöss, K., Simonović, N., Strobl, B., Macho-Maschler, S., & Müller, M. (2019). TYK2: An upstream kinase of STATs in cancer. Cancers, 11:1728. (woss2019tyk2anupstream pages 5-6, pages 6-8, pages 1-3, pages 3-5)
24. Bayliss, R., Haq, T., & Yeoh, S. (2015). The ‘ys and wherefores of protein kinase autoinhibition. Biochimica et Biophysica Acta (BBA) – Proteins and Proteomics, 1854:1586-1594. (bayliss2015theysand pages 20-25)
25. Dymock, B. W., Yang, E. G., Chu-Farseeva, Y., & Yao, L. (2014). Selective JAK inhibitors. Future Medicinal Chemistry, 6(12):1439-1471. (dymock2014selectivejakinhibitors. pages 24-25)
26. Krueger, J., McInnes, I., & Blauvelt, A. (2022). Tyrosine kinase 2 and Janus kinase–signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. Journal of the American Academy of Dermatology. (krueger2022tyrosinekinase2 pages 1-2)
27. Lesgidou, N., Eliopoulos, E., Goulielmos, G. N., & Vlassi, M. (2018). Insights on the alteration of functionality of a tyrosine kinase 2 variant: A molecular dynamics study. Bioinformatics, 34:i781-i786. (lesgidou2018insightsonthe pages 1-1, pages 6-6)
28. Li, Z., Gakovic, M., Ragimbeau, J., Eloranta, M.-L., Rönnblom, L., Michel, F., & Pellegrini, S. (2013). Two rare disease-associated TYK2 variants are catalytically impaired but signaling competent. The Journal of Immunology, 190:2335-2344. (li2013tworarediseaseassociated pages 9-9; li2017insightsontype pages 88-89, li2017insightsontypea pages 33-37)

References

1. (argiriadi2012enablingstructurebaseddrug pages 10-11): Maria A Argiriadi, Eric R Goedken, David Banach, David W Borhani, Andrew Burchat, Richard W Dixon, Doug Marcotte, Gary Overmeyer, Valerie Pivorunas, Ramkrishna Sadhukhan, Silvino Sousa, Nigel St Moore, Medha Tomlinson, Jeffrey Voss, Lu Wang, Neil Wishart, Kevin Woller, and Robert V Talanian. Enabling structure-based drug design of tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor. BMC Structural Biology, 12:22-22, Sep 2012. URL: https://doi.org/10.1186/1472-6807-12-22, doi:10.1186/1472-6807-12-22. This article has 20 citations and is from a peer-reviewed journal.
2. (borcherding2021tyk2incancer pages 14-16): Dana C. Borcherding, Kevin He, Neha V. Amin, and Angela C. Hirbe. Tyk2 in cancer metastases: genomic and proteomic discovery. Cancers, 13:4171, Aug 2021. URL: https://doi.org/10.3390/cancers13164171, doi:10.3390/cancers13164171. This article has 31 citations and is from a peer-reviewed journal.
3. (borcherding2021tyk2incancer pages 18-20): Dana C. Borcherding, Kevin He, Neha V. Amin, and Angela C. Hirbe. Tyk2 in cancer metastases: genomic and proteomic discovery. Cancers, 13:4171, Aug 2021. URL: https://doi.org/10.3390/cancers13164171, doi:10.3390/cancers13164171. This article has 31 citations and is from a peer-reviewed journal.
4. (borcherding2021tyk2incancer pages 3-5): Dana C. Borcherding, Kevin He, Neha V. Amin, and Angela C. Hirbe. Tyk2 in cancer metastases: genomic and proteomic discovery. Cancers, 13:4171, Aug 2021. URL: https://doi.org/10.3390/cancers13164171, doi:10.3390/cancers13164171. This article has 31 citations and is from a peer-reviewed journal.
5. (borcherding2021tyk2incancer pages 5-6): Dana C. Borcherding, Kevin He, Neha V. Amin, and Angela C. Hirbe. Tyk2 in cancer metastases: genomic and proteomic discovery. Cancers, 13:4171, Aug 2021. URL: https://doi.org/10.3390/cancers13164171, doi:10.3390/cancers13164171. This article has 31 citations and is from a peer-reviewed journal.
6. (gakovic2007functionalstudiesof pages 32-36): M Gakovic. Functional studies of tyk2 in ifnalpha signaling: a new interactor and an activating mutation. Unknown journal, 2007.
7. (gerstenberger2020discoveryoftyrosine pages 1-2): Brian S. Gerstenberger, Catherine Ambler, Eric P. Arnold, Mary-Ellen Banker, Matthew F. Brown, James D. Clark, Alpay Dermenci, Martin E. Dowty, Andrew Fensome, Susan Fish, Matthew M. Hayward, Martin Hegen, Brett D. Hollingshead, John D. Knafels, David W. Lin, Tsung H. Lin, Dafydd R. Owen, Eddine Saiah, Raman Sharma, Felix F. Vajdos, Li Xing, Xiaojing Yang, Xin Yang, and Stephen W. Wright. Discovery of tyrosine kinase 2 (tyk2) inhibitor (pf-06826647) for the treatment of autoimmune diseases. Journal of Medicinal Chemistry, 63:13561-13577, Aug 2020. URL: https://doi.org/10.1021/acs.jmedchem.0c00948, doi:10.1021/acs.jmedchem.0c00948. This article has 68 citations and is from a highest quality peer-reviewed journal.
8. (li2017insightsontype pages 9-14): Z Li. Insights on type i ifn signaling and regulation: studies of disease-associated tyk2 variants and of the negative regulators usp18/isg15. Unknown journal, 2017.
9. (li2017insightsontypea pages 14-20): Z Li. Insights on type i ifn signaling and regulation: studies of disease-associated tyk2 variants and of the negative regulators usp18/isg15. Unknown journal, 2017.
10. (li2017insightsontypea pages 88-89): Z Li. Insights on type i ifn signaling and regulation: studies of disease-associated tyk2 variants and of the negative regulators usp18/isg15. Unknown journal, 2017.
11. (lupardus2014structureofthe pages 1-2): Patrick J. Lupardus, Mark Ultsch, Heidi Wallweber, Pawan Bir Kohli, Adam R. Johnson, and Charles Eigenbrot. Structure of the pseudokinase–kinase domains from protein kinase tyk2 reveals a mechanism for janus kinase (jak) autoinhibition. Proceedings of the National Academy of Sciences, 111:8025-8030, May 2014. URL: https://doi.org/10.1073/pnas.1401180111, doi:10.1073/pnas.1401180111. This article has 228 citations.
12. (lupardus2014structureofthe pages 2-3): Patrick J. Lupardus, Mark Ultsch, Heidi Wallweber, Pawan Bir Kohli, Adam R. Johnson, and Charles Eigenbrot. Structure of the pseudokinase–kinase domains from protein kinase tyk2 reveals a mechanism for janus kinase (jak) autoinhibition. Proceedings of the National Academy of Sciences, 111:8025-8030, May 2014. URL: https://doi.org/10.1073/pnas.1401180111, doi:10.1073/pnas.1401180111. This article has 228 citations.
13. (min2015structuralandfunctional pages 1-2): Xiaoshan Min, Daniela Ungureanu, Sarah Maxwell, Henrik Hammarén, Steve Thibault, Ellin-Kristina Hillert, Merrill Ayres, Brad Greenfield, John Eksterowicz, Chris Gabel, Nigel Walker, Olli Silvennoinen, and Zhulun Wang. Structural and functional characterization of the jh2 pseudokinase domain of jak family tyrosine kinase 2 (tyk2). Journal of Biological Chemistry, 290:27261-27270, Nov 2015. URL: https://doi.org/10.1074/jbc.m115.672048, doi:10.1074/jbc.m115.672048. This article has 108 citations and is from a domain leading peer-reviewed journal.
14. (min2015structuralandfunctional pages 4-6): Xiaoshan Min, Daniela Ungureanu, Sarah Maxwell, Henrik Hammarén, Steve Thibault, Ellin-Kristina Hillert, Merrill Ayres, Brad Greenfield, John Eksterowicz, Chris Gabel, Nigel Walker, Olli Silvennoinen, and Zhulun Wang. Structural and functional characterization of the jh2 pseudokinase domain of jak family tyrosine kinase 2 (tyk2). Journal of Biological Chemistry, 290:27261-27270, Nov 2015. URL: https://doi.org/10.1074/jbc.m115.672048, doi:10.1074/jbc.m115.672048. This article has 108 citations and is from a domain leading peer-reviewed journal.
15. (muromoto2022currentunderstandingof pages 1-2): R. Muromoto, K. Oritani, and T. Matsuda. Current understanding of the role of tyrosine kinase 2 signaling in immune responses. World Journal of Biological Chemistry, 13:1-14, Jan 2022. URL: https://doi.org/10.4331/wjbc.v13.i1.1, doi:10.4331/wjbc.v13.i1.1. This article has 45 citations.
16. (rusinol2023tyk2targetingin pages 1-3): Lluís Rusiñol and Luis Puig. Tyk2 targeting in immune-mediated inflammatory diseases. International Journal of Molecular Sciences, 24:3391, Feb 2023. URL: https://doi.org/10.3390/ijms24043391, doi:10.3390/ijms24043391. This article has 50 citations and is from a peer-reviewed journal.
17. (sohn2013arestrictedrole pages 12-13): Sue J Sohn, Kathy Barrett, Anne Van Abbema, Christine Chang, Pawan Bir Kohli, Hidenobu Kanda, Janice Smith, Yingjie Lai, Aihe Zhou, Birong Zhang, Wenqian Yang, Karen Williams, Calum Macleod, Christopher A Hurley, Janusz J Kulagowski, Nicholas Lewin-Koh, Hart S Dengler, Adam R Johnson, Nico Ghilardi, Mark Zak, Jun Liang, Wade S Blair, Steven Magnuson, and Lawren C Wu. A restricted role for tyk2 catalytic activity in human cytokine responses revealed by novel tyk2-selective inhibitors. The Journal of Immunology, 191:2205-2216, Sep 2013. URL: https://doi.org/10.4049/jimmunol.1202859, doi:10.4049/jimmunol.1202859. This article has 132 citations.
18. (tokarski2015tyrosinekinase2mediated pages 1-2): John S. Tokarski, Adriana Zupa-Fernandez, Jeffrey A. Tredup, Kristen Pike, ChiehYing Chang, Dianlin Xie, Lihong Cheng, Donna Pedicord, Jodi Muckelbauer, Stephen R. Johnson, Sophie Wu, Suzanne C. Edavettal, Yang Hong, Mark R. Witmer, Lisa L. Elkin, Yuval Blat, William J. Pitts, David S. Weinstein, and James R. Burke. Tyrosine kinase 2-mediated signal transduction in t lymphocytes is blocked by pharmacological stabilization of its pseudokinase domain. Journal of Biological Chemistry, 290:11061-11074, Apr 2015. URL: https://doi.org/10.1074/jbc.m114.619502, doi:10.1074/jbc.m114.619502. This article has 120 citations and is from a domain leading peer-reviewed journal.
19. (turrubiartesmartinez2020tyk2variantsin pages 15-16): Edgar Turrubiartes-Martínez, Irene Bodega-Mayor, Pablo Delgado-Wicke, Francisca Molina-Jiménez, Diana Casique-Aguirre, Martín González-Andrade, Inmaculada Rapado, Mireia Camós, Cristina Díaz-de-Heredia, Eva Barragán, Manuel Ramírez-Orellana, Beatriz Aguado, Ángela Figuera, Joaquín Martínez-López, and Elena Fernández-Ruiz. Tyk2 variants in b-acute lymphoblastic leukaemia. Genes, 11:1434, Nov 2020. URL: https://doi.org/10.3390/genes11121434, doi:10.3390/genes11121434. This article has 5 citations and is from a peer-reviewed journal.
20. (woss2019tyk2anupstream pages 5-6): K. Wöss, Natalija Simonović, B. Strobl, Sabine Macho-Maschler, and Mathias Müller. Tyk2: an upstream kinase of stats in cancer. Cancers, Nov 2019. URL: https://doi.org/10.3390/cancers11111728, doi:10.3390/cancers11111728. This article has 61 citations and is from a peer-reviewed journal.
21. (bayliss2015theysand pages 20-25): Richard Bayliss, Tamanna Haq, and Sharon Yeoh. The ys and wherefores of protein kinase autoinhibition. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 1854:1586-1594, Oct 2015. URL: https://doi.org/10.1016/j.bbapap.2015.04.025, doi:10.1016/j.bbapap.2015.04.025. This article has 21 citations.
22. (dymock2014selectivejakinhibitors. pages 24-25): Brian W Dymock, Eugene Guorong Yang, Yuyi Chu-Farseeva, and Lianbin Yao. Selective jak inhibitors. Future medicinal chemistry, 6 12:1439-71, Oct 2014. URL: https://doi.org/10.4155/fmc.14.92, doi:10.4155/fmc.14.92. This article has 48 citations and is from a peer-reviewed journal.
23. (krueger2022tyrosinekinase2 pages 1-2): J. Krueger, I. McInnes, and A. Blauvelt. Tyrosine kinase 2 and janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. Journal of the American Academy of Dermatology, Jul 2022. URL: https://doi.org/10.1016/j.jaad.2021.06.869, doi:10.1016/j.jaad.2021.06.869. This article has 111 citations and is from a domain leading peer-reviewed journal.
24. (lesgidou2018insightsonthe pages 1-1): Nastazia Lesgidou, Elias Eliopoulos, George N Goulielmos, and Metaxia Vlassi. Insights on the alteration of functionality of a tyrosine kinase 2 variant: a molecular dynamics study. Bioinformatics, 34:i781-i786, Sep 2018. URL: https://doi.org/10.1093/bioinformatics/bty556, doi:10.1093/bioinformatics/bty556. This article has 19 citations and is from a highest quality peer-reviewed journal.
25. (li2013tworarediseaseassociated pages 9-9): Zhi Li, Milica Gakovic, Josiane Ragimbeau, Maija-Leena Eloranta, Lars Rönnblom, Frédérique Michel, and Sandra Pellegrini. Two rare disease-associated tyk2 variants are catalytically impaired but signaling competent. The Journal of Immunology, 190:2335-2344, Mar 2013. URL: https://doi.org/10.4049/jimmunol.1203118, doi:10.4049/jimmunol.1203118. This article has 81 citations.
26. (li2017insightsontype pages 88-89): Z Li. Insights on type i ifn signaling and regulation: studies of disease-associated tyk2 variants and of the negative regulators usp18/isg15. Unknown journal, 2017.
27. (li2017insightsontypea pages 30-33): Z Li. Insights on type i ifn signaling and regulation: studies of disease-associated tyk2 variants and of the negative regulators usp18/isg15. Unknown journal, 2017.
28. (li2017insightsontypea pages 33-37): Z Li. Insights on type i ifn signaling and regulation: studies of disease-associated tyk2 variants and of the negative regulators usp18/isg15. Unknown journal, 2017.
29. (min2015structuralandfunctional pages 10-11): Xiaoshan Min, Daniela Ungureanu, Sarah Maxwell, Henrik Hammarén, Steve Thibault, Ellin-Kristina Hillert, Merrill Ayres, Brad Greenfield, John Eksterowicz, Chris Gabel, Nigel Walker, Olli Silvennoinen, and Zhulun Wang. Structural and functional characterization of the jh2 pseudokinase domain of jak family tyrosine kinase 2 (tyk2). Journal of Biological Chemistry, 290:27261-27270, Nov 2015. URL: https://doi.org/10.1074/jbc.m115.672048, doi:10.1074/jbc.m115.672048. This article has 108 citations and is from a domain leading peer-reviewed journal.
30. (min2015structuralandfunctional pages 6-7): Xiaoshan Min, Daniela Ungureanu, Sarah Maxwell, Henrik Hammarén, Steve Thibault, Ellin-Kristina Hillert, Merrill Ayres, Brad Greenfield, John Eksterowicz, Chris Gabel, Nigel Walker, Olli Silvennoinen, and Zhulun Wang. Structural and functional characterization of the jh2 pseudokinase domain of jak family tyrosine kinase 2 (tyk2). Journal of Biological Chemistry, 290:27261-27270, Nov 2015. URL: https://doi.org/10.1074/jbc.m115.672048, doi:10.1074/jbc.m115.672048. This article has 108 citations and is from a domain leading peer-reviewed journal.
31. (min2015structuralandfunctional pages 7-8): Xiaoshan Min, Daniela Ungureanu, Sarah Maxwell, Henrik Hammarén, Steve Thibault, Ellin-Kristina Hillert, Merrill Ayres, Brad Greenfield, John Eksterowicz, Chris Gabel, Nigel Walker, Olli Silvennoinen, and Zhulun Wang. Structural and functional characterization of the jh2 pseudokinase domain of jak family tyrosine kinase 2 (tyk2). Journal of Biological Chemistry, 290:27261-27270, Nov 2015. URL: https://doi.org/10.1074/jbc.m115.672048, doi:10.1074/jbc.m115.672048. This article has 108 citations and is from a domain leading peer-reviewed journal.
32. (muromoto2022currentunderstandingof pages 10-11): R. Muromoto, K. Oritani, and T. Matsuda. Current understanding of the role of tyrosine kinase 2 signaling in immune responses. World Journal of Biological Chemistry, 13:1-14, Jan 2022. URL: https://doi.org/10.4331/wjbc.v13.i1.1, doi:10.4331/wjbc.v13.i1.1. This article has 45 citations.
33. (muromoto2022currentunderstandingof pages 2-4): R. Muromoto, K. Oritani, and T. Matsuda. Current understanding of the role of tyrosine kinase 2 signaling in immune responses. World Journal of Biological Chemistry, 13:1-14, Jan 2022. URL: https://doi.org/10.4331/wjbc.v13.i1.1, doi:10.4331/wjbc.v13.i1.1. This article has 45 citations.